Betaseron Sales Data
| Rank 98 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Betaseron U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 98 ( 5) |
$179,216 | -3.72% | 116 | -3.33% |
| Q3 2013 | 93 (6) |
$186,143 | -1.62% | 120 | 37.93% |
| Q2 2013 | 87 | $189,215 | -3.25% | 87 | 52.63% |
| Q1 2013 | 87 (5) |
$195,574 | -3.20% | 57 | -6.56% |
| Q4 2012 | 82 (5) |
$202,032 | -0.56% | 61 | -3.17% |
| Q3 2012 | 77 ( 11) |
$203,170 | 11.98% | 63 | 6.78% |
| Q2 2012 | 88 (10) |
$181,439 | 5.40% | 59 | -11.94% |
| Q1 2012 | 98 (1) |
$172,143 | 2.93% | 67 | -10.67% |
| Q4 2011 | 99 (12) |
$167,236 | -3.76% | 75 | -5.06% |
| Q3 2011 | 87 (2) |
$173,769 | -2.89% | 79 | -2.47% |
| Q2 2011 | 89 (4) |
$178,938 | -2.17% | 81 | -7.95% |
| Q1 2011 | 85 | $182,908 | n/a | 88 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
